A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors

Trial Profile

A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Mar 2016

At a glance

  • Drugs Capecitabine (Primary) ; Temozolomide (Primary)
  • Indications Neuroendocrine tumours; Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 08 Mar 2016 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
    • 02 Jun 2015 The first patient entered the study in August 2013 and 67 patients (46% of the target) were enrolled as of January 2015, according to an abstract at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top